Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication.
We determined systemic oxidative stress in Parkinson's disease (PD) patients, patients with other neurological diseases (OND) and healthy controls by measurement of in vitro lipoprotein oxidation and levels of hydro- and lipophilic antioxidants in plasma and cerebrospinal fluid (CSF). Additionally, we investigated the influence of levodopa (LD) and dopamine agonist therapy (DA) on the oxidative status in PD patients. We found increased oxidative stress, seen as higher levels of lipoprotein oxidation in plasma and CSF, decrease of plasma levels of protein sulfhydryl (SH) groups and lower CSF levels of alpha-tocopherol in PD patients compared to OND patients and controls. Levodopa treatment did not significantly change the plasma lipoprotein oxidation but LD monotherapy tended to result in an increase of autooxidation and in a decrease of plasma antioxidants with significance for ubiquinol-10. DA monotherapy was significantly associated with higher alpha-tocopherol levels. Patients with DA monotherapy or co-medication with DA showed a trend to lower lipoprotein oxidation. These data support the concept of oxidative stress as a factor in the pathogenesis of PD and might be an indicator of a potential prooxidative role of LD and a possible antioxidative effect of DA in PD treatment.
Buhmann
Carsten
C
Neurological Department, University Clinic Hamburg-Eppendorf, D-20246 Hamburg, Germany. buhmann@uke.uni-hamburg.de
Arlt
Sönke
S
Kontush
Anatol
A
Möller-Bertram
Tobias
T
Sperber
Sinje
S
Oechsner
Matthias
M
Stuerenburg
Hans Joerg
HJ
Beisiegel
Ulrike
U
D000328:Adult; D000975:Antioxidants / Q000378:metabolism; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001205:Ascorbic Acid / Q000097:blood; D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008074:Lipoproteins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology*; D010300:Parkinson Disease / Q000097:blood* / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012016:Reference Values; D013438:Sulfhydryl Compounds / Q000097:blood; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology; D024502:alpha-Tocopherol / Q000134:cerebrospinal fluid
D000975:Antioxidants; D000978:Antiparkinson Agents; D015415:Biomarkers; D008074:Lipoproteins; D013438:Sulfhydryl Compounds; D014451:Ubiquinone; D007980:Levodopa; D024502:alpha-Tocopherol; C003741:ubiquinol; D001205:Ascorbic Acid; D004298:Dopamine